Clinical Trial Details
Braintumor Website

[Information provided by: ClinicalTrials.gov, which provides patients, family members, and members of the public easy and free access to information on clinical studies for a wide range of diseases and conditions.]

NCT01622868 : Whole-Brain Radiation Therapy or Stereotactic Radiosurgery With or Without Lapatinib Ditosylate in Treating Patients With Brain Metastasis From HER2-Positive Breast Cancer
PhasePhase 2
AgesMin: 18 Years Max: N/A
Eligibility
Inclusion Criteria:

- Pathologically (histologically or cytologically) proven diagnosis of invasive breast
cancer

- HER2-overexpressing breast cancer (3+ staining by immunohistochemistry or HER2 gene
amplification by fluorescent in situ hybridization [FISH] or silver in situ
hybridization [SISH] >= 2.0)

- At least 1 measurable and no more than 10 unirradiated parenchymal brain metastasis
within 21 days prior to study entry; the minimum size as measured on T1-weighted
gadolinium-enhanced MRI must be as follows according to the number of brain
metastases:

- For a single solitary lesion the size must be >= 10 mm

- For 2 or more lesions, the size of at least 2 of the lesions must be >= 5 mm

- Patients may also have the following provided the size requirements above are
met:

- Progressive parenchymal brain metastasis following stereotactic
radiosurgery for 1-3 brain metastases, with at least 1 new measurable brain
lesion

- Progressive parenchymal brain metastasis following surgical resection of
1-3 brain metastases, with at least 1 measurable brain lesion

- History/physical examination within 21 days prior to study entry

- Karnofsky performance status >= 60 within 21 days prior to study entry

- Able to swallow and retain oral medication (note: for patients unable to swallow
tablets, an oral suspension preparation is acceptable)

- Absolute neutrophil count (ANC) >= 1,200 cells/mm^3

- Platelets >= 70,000 cells/mm^3

- Hemoglobin >= 8.0 g/dL (note: the use of transfusion or other intervention to achieve
hemoglobin [Hgb] >= 8.0 g/dL is acceptable)

- Creatinine < 1.5 times institutional upper limit of normal

- Bilirubin < 1.5 times institutional upper limit of normal

- Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3.0 times
institutional upper limit of normal with or without liver metastasis

- Patient must provide study specific informed consent prior to study entry

- Women of childbearing potential must have a negative serum pregnancy test within 21
days prior to study entry

- Sexually active women of childbearing potential and sexually active men must practice
adequate contraception during therapy and for 12 months after protocol treatment
completion

- Prior lapatinib is allowed as long as the last dose received was > 21 days prior to
study entry and provided the patient has not received it at any time after the
diagnosis of brain metastasis

Exclusion Criteria:

- Prior WBRT

- Prior radiation therapy (RT) (any site) with concurrent lapatinib defined as 1 or
more days on which the patient received both radiation therapy and lapatinib on the
same day

- Uncontrolled intercurrent illness including, but not limited to, ongoing or active
infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
arrhythmia, or psychiatric illness/social situations that would limit compliance with
study requirements

- Prior invasive malignancy (except non-melanomatous skin cancer, curatively resected
thyroid papillary carcinoma, and invasive and non-invasive cancers related to the
breast cancer) unless disease free for a minimum of 3 years

- Leptomeningeal disease

- Prior radiotherapy to the region of the study cancer that would result in overlap of
radiation therapy fields except patients who have progressed following stereotactic
radiosurgery for 1-3 brain metastases, with at least one new lesion

- Severe, active co-morbidity, defined as follows:

- Unstable angina and/or congestive heart failure requiring hospitalization within
the last 6 months

- Transmural myocardial infarction within the last 6 months

- Acute bacterial or fungal infection requiring intravenous antibiotics at the
time of study entry

- Chronic obstructive pulmonary disease exacerbation or other respiratory illness
requiring hospitalization or precluding study therapy at the time of study entry

- Hepatic insufficiency resulting in clinical jaundice and/or coagulation defects;
hepatic or biliary disease that is acute or currently active or that requires
antiviral therapy (with the exception of patients with Gilbert's syndrome,
asymptomatic gallstones, liver metastases, or stable chronic liver disease per
investigator assessment)

- History of left ventricular ejection fraction (LVEF) below institutional normal
unless repeated and within institutional normal range within 90 days of study
entry

- Grade 2 or greater rash of any cause at time of study entry

- Grade 2 or greater diarrhea of any cause at time of study entry
LinksPermanent Link to THIS page: http://virtualtrials.com/nct/display1trial.cfm?nct=NCT01622868      |      Link to official Clinicaltrials.gov listing
Locations
South Bend, Indiana
Facility: Northern Indiana Cancer Research Consortium
Investigator: Binh N. Tran
Contact: Binh N. Tran Phone: 574-237-1328
Email not avaialable

Mount Holly, New Jersey
Facility: Virtua Memorial
Investigator: Lemuel S. Ariaratnam
Contact: Lemuel S. Ariaratnam Phone: 609-914-6762
Email not avaialable

Rochester, New York
Facility: University of Rochester
Investigator: Yuhchyau Chen
Contact: Yuhchyau Chen Phone: 585-275-5830
Email not avaialable




Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2017 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740


Website Design By
World Wide Websites